Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17021364 | 0.92 | SYK (0.35) | KDRJAK2CSF1R | |
| SCHEMBL2696001 | 0.82 | JAK3 (0.50) | JAK2CSF1R | |
| SCHEMBL19010332 | 0.80 | GFER (0.49) | JAK2BRD4MAPTTDP1 | |
| SCHEMBL19010343 | 0.80 | JAK2 (0.40) | JAK2BRD4 | |
| SCHEMBL19010360 | 0.79 | JAK3 (0.42) | JAK2 | |
| SCHEMBL19010335 | 0.79 | FFAR1 (0.41) | KDRJAK2 | |
| SCHEMBL19010350 | 0.78 | JAK3 (0.39) | JAK2MAPT | |
| SCHEMBL19010351 | 0.78 | JAK3 (0.36) | JAK2 | |
| SCHEMBL19010352 | 0.76 | IRAK4 (0.39) | JAK2 | |
| SCHEMBL19010366 | 0.76 | JAK3 (0.38) | JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834548-B2 | Pyridazine compounds as JAK inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK2, JAK3 | KDR 1544/4885JAK2 2/4885BRD4 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.